Taiho Oncology, Inc., a company developing and commercializing novel therapies for hematologic malignancies and solid tumors, announced that it will present new data from five studies, including two oral presentations, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3 at McCormick Place in Chicago.
The oral presentations will feature data on ASTX727 (oral decitabine-cedapyridine), an approved treatment for myelodysplastic syndrome (MDS), paired with venetoclax for the treatment of acute myeloid leukemia (AML), and zipalertinib, a novel investigational candidate for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
The company will also share data from three real-world studies of two FDA-approved therapies: trifluridine and tipiracil paired with bevacizumab for late-line treatment of adult patients with metastatic colorectal cancer, and fultibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma.
“ASCO provides a valuable opportunity to bring together the best minds in oncology to discuss emerging therapies and our understanding of how existing therapies work in the real world,” said Harold Keer, MD, Chief Medical Officer of Taiho Oncology.
Our data at ASCO continue to demonstrate our unwavering commitment to meaningful innovations that have the potential to improve the lives of cancer patients, their families and caregivers.”
Related topics:
